Last reviewed 2026-04-20 · How we verify

MS Contin (morphine sulfate)

The prototypical opioid agonist that binds mu-opioid receptors in the CNS, providing potent analgesia and serving as the reference standard for all opioids.

Morphine is the prototypical opioid and reference standard for all opioid analgesics, isolated from opium in 1804. Remains the gold standard for severe pain management. Schedule II controlled substance. WHO Essential Medicine.

At a glance

Mechanism of action

Morphine is the prototypical opioid against which all others are compared. Isolated from opium in 1804, it remains the gold standard for severe pain management. It activates mu-opioid receptors in the brain and spinal cord, inhibiting ascending pain pathways and altering pain perception. Available in numerous formulations for different clinical scenarios.

Approved indications

• Acute postoperative pain
• Chronic Pain with Opioid Tolerance
• Chronic pain
• Diarrhea
• General anesthesia
• Local anesthesia
• Pain
• Regional Anesthesia for Labor Pain
• Regional Anesthesia for Surgery
• Severe pain

Boxed warnings

• WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE TABLETS Addiction, Abuse, and Misuse Because the use of morphine sulfate tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of morphine sulfate tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of morphine sulfate tablets are essential [see Warnings and Precautions ( 5.2 )]. Accidental Ingestion Accidental ingestion of even one dose of morphine sulfate tablets, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions ( 5.2 )] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine sulfate tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions ( 5.3 ), Drug Interactions ( 7 )]. Neonatal Opioid Withdrawal Syndrome (NOWS) If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions ( 5.4 )]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions ( 5.5 )]. WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MORPHINE SULFATE TABLETS See full prescribing information for complete boxed warning. Morphine sulfate tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and regularly evaluate for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of morphine sulfate tablets are essential. ( 5.2 ) Accidental ingestion of morphine sulfate tablets, especially by children, can result in a fatal overdose of morphine. ( 5.2 ) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. ( 5.3 , 7 ) If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. ( 5.4 ) Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. ( 5.5 )

Common side effects

• Constipation
• Nausea
• Sedation
• Dizziness
• Vomiting
• Sweating
• Dysphoria
• Euphoric mood
• Tachycardia
• Bradycardia
• Palpitations
• Visual impairment

Serious adverse events

• Respiratory depression
• Apnea
• Respiratory arrest
• Circulatory depression
• Hypotension
• Shock
• Serotonin syndrome
• Adrenal insufficiency
• Anaphylaxis
• Androgen deficiency

Key clinical trials

• Post Operative Pain Control: Continuous Infusion of Morphine vs Fentanyl. Clinical Outcomes (NA)
• A Single Centre Randomized Controlled Trial To Evaluate Dronabinol For Acute Pain Management In Adults With Traumatic Injury (Phase 2)
• The Effect of Neuraxial Morphine (Duramorph) on Pain Control (EARLY/Phase 1)
• "Comparison of Rhomboid Intercostal and Subserratus Plane Blocks Applied for Postoperative Analgesia in Video-Assisted Thoracoscopic Surgery With Thoracic Paravertebral Block" (NA)
• Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing: an Exploratory Study in Healthy Volunteers (The Polo Study) (Phase 4)
• Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department (Phase 1)
• Titration Morphinique autocontrôlée Par le Patient Par un Dispositif mécanique à Usage Unique Versus Administration Par l'infirmière Chez Les Patients Ayant Une Douleur aiguë sévère Aux Urgences. (Phase 4)
• Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery (Phase 4)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MS Contin CI brief — competitive landscape report
• MS Contin updates RSS · CI watch RSS
• Generic (multiple manufacturers) portfolio CI